An Open-label, Multi-drug, Multi-center Phase II Combination Study of AZD4635 in Patients with Prostate Cancer
Study of AZD4635 in Patients with Prostate Cancer
Sponsor: AstraZeneca
Enrolling: Male Patients Only
IRB Number: AAAS6539
U.S. Govt. ID: NCT04089553
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: The purpose of this study is to find a more effective treatment as well as to gain a better understanding of prostate cancer. This study includes investigational study drugs which are specific for your prostate cancer (module). Treatment in each module will include an investigational medication called AZD4635 as well as another module-specific study drug(s). The combination of AZD4635 and the module-specific drug(s) is expected to stimulate your immune system to help fight your cancer.
This study is closed
Emerson Lim, MD
Do You Qualify?
Are you a male of at least 18 years of age? Yes No
Do you have prostate cancer? Yes No
Have you taken standard of care therapies? Yes No
Are you able to perform everyday work independently? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator